HUE034962T2 - Anti-CD38 antibodies for the treatment of multiple myeloma - Google Patents

Info

Publication number

HUE034962T2

HUE034962T2 HUE12178778A HUE12178778A HUE034962T2 HU E034962 T2 HUE034962 T2 HU E034962T2 HU E12178778 A HUE12178778 A HU E12178778A HU E12178778 A HUE12178778 A HU E12178778A HU E034962 T2 HUE034962 T2 HU E034962T2

Authority

HU

Hungary

Prior art keywords

antibody

seq

human

sequence

binding

Prior art date

2005-03-23

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 title claims description 16
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 title description 388
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 title description 259
• 206010035226 Plasma cell myeloma Diseases 0.000 title description 36
• 208000034578 Multiple myelomas Diseases 0.000 title description 24
• 241000282414 Homo sapiens Species 0.000 claims description 341
• 230000027455 binding Effects 0.000 claims description 276
• 210000004027 cell Anatomy 0.000 claims description 260
• 238000000034 method Methods 0.000 claims description 192
• 108090000623 proteins and genes Proteins 0.000 claims description 141
• 150000007523 nucleic acids Chemical class 0.000 claims description 137
• 102000039446 nucleic acids Human genes 0.000 claims description 126
• 108020004707 nucleic acids Proteins 0.000 claims description 126
• 239000000427 antigen Substances 0.000 claims description 106
• 108091007433 antigens Proteins 0.000 claims description 102
• 102000036639 antigens Human genes 0.000 claims description 102
• 239000013598 vector Substances 0.000 claims description 89
• 102000004169 proteins and genes Human genes 0.000 claims description 72
• 239000013604 expression vector Substances 0.000 claims description 59
• 230000014509 gene expression Effects 0.000 claims description 57
• 239000003814 drug Substances 0.000 claims description 37
• 239000000203 mixture Substances 0.000 claims description 32
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 30
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 30
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
• 229940127121 immunoconjugate Drugs 0.000 claims description 27
• -1 amine salt Chemical class 0.000 claims description 22
• 229940124597 therapeutic agent Drugs 0.000 claims description 18
• 201000010099 disease Diseases 0.000 claims description 17
• 229940079593 drug Drugs 0.000 claims description 17
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
• 239000003795 chemical substances by application Substances 0.000 claims description 16
• 230000001225 therapeutic effect Effects 0.000 claims description 16
• 239000008194 pharmaceutical composition Substances 0.000 claims description 15
• 230000015572 biosynthetic process Effects 0.000 claims description 14
• 208000035475 disorder Diseases 0.000 claims description 12
• 208000032839 leukemia Diseases 0.000 claims description 11
• 210000004698 lymphocyte Anatomy 0.000 claims description 10
• 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
• 239000012528 membrane Substances 0.000 claims description 9
• 210000004379 membrane Anatomy 0.000 claims description 9
• 239000002253 acid Substances 0.000 claims description 8
• 230000000670 limiting effect Effects 0.000 claims description 8
• 230000001413 cellular effect Effects 0.000 claims description 7
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 6
• 230000001939 inductive effect Effects 0.000 claims description 6
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 5
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
• 208000015230 aggressive NK-cell leukemia Diseases 0.000 claims description 4
• 210000004556 brain Anatomy 0.000 claims description 4
• 230000001684 chronic effect Effects 0.000 claims description 4
• 230000008878 coupling Effects 0.000 claims description 4
• 238000010168 coupling process Methods 0.000 claims description 4
• 238000005859 coupling reaction Methods 0.000 claims description 4
• 230000002519 immonomodulatory effect Effects 0.000 claims description 4
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
• 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims description 3
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
• 239000003018 immunosuppressive agent Substances 0.000 claims description 3
• 230000003278 mimic effect Effects 0.000 claims description 3
• 230000004913 activation Effects 0.000 claims description 2
• 230000000527 lymphocytic effect Effects 0.000 claims description 2
• 238000002054 transplantation Methods 0.000 claims description 2
• 230000001926 lymphatic effect Effects 0.000 claims 4
• 210000003097 mucus Anatomy 0.000 claims 3
• 206010025323 Lymphomas Diseases 0.000 claims 2
• NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims 1
• 206010015995 Eyelid ptosis Diseases 0.000 claims 1
• 206010017533 Fungal infection Diseases 0.000 claims 1
• 206010018691 Granuloma Diseases 0.000 claims 1
• 102000003729 Neprilysin Human genes 0.000 claims 1
• 108090000028 Neprilysin Proteins 0.000 claims 1
• 241000819999 Nymphes Species 0.000 claims 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
• 241000985694 Polypodiopsida Species 0.000 claims 1
• 208000000389 T-cell leukemia Diseases 0.000 claims 1
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
• 208000025865 Ulcer Diseases 0.000 claims 1
• 230000001154 acute effect Effects 0.000 claims 1
• 238000002399 angioplasty Methods 0.000 claims 1
• 230000000507 anthelmentic effect Effects 0.000 claims 1
• 201000001034 autosomal recessive chronic granulomatous disease cytochrome b-positive type III Diseases 0.000 claims 1
• 238000003763 carbonization Methods 0.000 claims 1
• 230000009920 chelation Effects 0.000 claims 1
• 239000012829 chemotherapy agent Substances 0.000 claims 1
• 229940124558 contraceptive agent Drugs 0.000 claims 1
• 239000003433 contraceptive agent Substances 0.000 claims 1
• 201000003146 cystitis Diseases 0.000 claims 1
• 208000037902 enteropathy Diseases 0.000 claims 1
• 208000028104 epidemic louse-borne typhus Diseases 0.000 claims 1
• 208000024386 fungal infectious disease Diseases 0.000 claims 1
• 230000000855 fungicidal effect Effects 0.000 claims 1
• 239000000417 fungicide Substances 0.000 claims 1
• 210000002758 humerus Anatomy 0.000 claims 1
• 210000003016 hypothalamus Anatomy 0.000 claims 1
• 229940125721 immunosuppressive agent Drugs 0.000 claims 1
• 208000028774 intestinal disease Diseases 0.000 claims 1
• 210000000936 intestine Anatomy 0.000 claims 1
• 239000006166 lysate Substances 0.000 claims 1
• 235000019988 mead Nutrition 0.000 claims 1
• 210000002850 nasal mucosa Anatomy 0.000 claims 1
• 230000002956 necrotizing effect Effects 0.000 claims 1
• 229910052759 nickel Inorganic materials 0.000 claims 1
• PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 1
• 230000002093 peripheral effect Effects 0.000 claims 1
• 229910052698 phosphorus Inorganic materials 0.000 claims 1
• 239000011574 phosphorus Substances 0.000 claims 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
• 229920001084 poly(chloroprene) Polymers 0.000 claims 1
• 201000003004 ptosis Diseases 0.000 claims 1
• 210000002325 somatostatin-secreting cell Anatomy 0.000 claims 1
• 208000011580 syndromic disease Diseases 0.000 claims 1
• 206010061393 typhus Diseases 0.000 claims 1
• 231100000397 ulcer Toxicity 0.000 claims 1
• 230000002861 ventricular Effects 0.000 claims 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 153
• 102000052645 human CD38 Human genes 0.000 description 131
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 127
• 150000001413 amino acids Chemical class 0.000 description 113
• 125000003275 alpha amino acid group Chemical group 0.000 description 96
• 102000004196 processed proteins & peptides Human genes 0.000 description 67
• 235000018102 proteins Nutrition 0.000 description 67
• 235000001014 amino acid Nutrition 0.000 description 60
• 229940024606 amino acid Drugs 0.000 description 57
• 125000000539 amino acid group Chemical group 0.000 description 57
• 108060003951 Immunoglobulin Proteins 0.000 description 54
• 102000018358 immunoglobulin Human genes 0.000 description 54
• 239000012634 fragment Substances 0.000 description 50
• 239000002773 nucleotide Substances 0.000 description 49
• 125000003729 nucleotide group Chemical group 0.000 description 49
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 47
• 230000004048 modification Effects 0.000 description 41
• 238000012986 modification Methods 0.000 description 41
• 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 38
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 38
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 37
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 37
• 230000005764 inhibitory process Effects 0.000 description 33
• 210000004408 hybridoma Anatomy 0.000 description 32
• 229920001184 polypeptide Polymers 0.000 description 31
• 108091028043 Nucleic acid sequence Proteins 0.000 description 29
• 238000006467 substitution reaction Methods 0.000 description 29
• 102000005962 receptors Human genes 0.000 description 28
• 108020003175 receptors Proteins 0.000 description 28
• 230000000890 antigenic effect Effects 0.000 description 27
• 239000013603 viral vector Substances 0.000 description 27
• 241001465754 Metazoa Species 0.000 description 26
• 210000004602 germ cell Anatomy 0.000 description 26
• 230000009261 transgenic effect Effects 0.000 description 26
• 238000004519 manufacturing process Methods 0.000 description 25
• 206010028980 Neoplasm Diseases 0.000 description 24
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 24
• 239000012636 effector Substances 0.000 description 23
• 210000003719 b-lymphocyte Anatomy 0.000 description 22
• COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 22
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 22
• 241000894007 species Species 0.000 description 22
• 241000699670 Mus sp. Species 0.000 description 21
• 229940027941 immunoglobulin g Drugs 0.000 description 21
• 239000003053 toxin Substances 0.000 description 21
• 231100000765 toxin Toxicity 0.000 description 21
• 108700012359 toxins Proteins 0.000 description 21
• 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 20
• 230000006870 function Effects 0.000 description 19
• 241000699666 Mus <mouse, genus> Species 0.000 description 18
• 231100000599 cytotoxic agent Toxicity 0.000 description 18
• 108700019146 Transgenes Proteins 0.000 description 17
• 108020001507 fusion proteins Proteins 0.000 description 17
• 102000037865 fusion proteins Human genes 0.000 description 17
• 238000001727 in vivo Methods 0.000 description 17
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 17
• 108020004414 DNA Proteins 0.000 description 16
• 201000011510 cancer Diseases 0.000 description 16
• 230000009089 cytolysis Effects 0.000 description 16
• 238000010186 staining Methods 0.000 description 16
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 15
• 230000004927 fusion Effects 0.000 description 15
• 230000013595 glycosylation Effects 0.000 description 15
• 238000006206 glycosylation reaction Methods 0.000 description 15
• 238000003780 insertion Methods 0.000 description 15
• 230000037431 insertion Effects 0.000 description 15
• 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 14
• 108090000994 Catalytic RNA Proteins 0.000 description 14
• 102000053642 Catalytic RNA Human genes 0.000 description 14
• 229940127089 cytotoxic agent Drugs 0.000 description 14
• 230000028993 immune response Effects 0.000 description 14
• 230000001965 increasing effect Effects 0.000 description 14
• 230000001404 mediated effect Effects 0.000 description 14
• 239000002245 particle Substances 0.000 description 14
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
• 108091092562 ribozyme Proteins 0.000 description 14
• 102000004190 Enzymes Human genes 0.000 description 13
• 108090000790 Enzymes Proteins 0.000 description 13
• 108010087819 Fc receptors Proteins 0.000 description 13
• 102000009109 Fc receptors Human genes 0.000 description 13
• 241000124008 Mammalia Species 0.000 description 13
• 241000700605 Viruses Species 0.000 description 13
• 230000001472 cytotoxic effect Effects 0.000 description 13
• 229940088598 enzyme Drugs 0.000 description 13
• 230000006698 induction Effects 0.000 description 13
• 239000013612 plasmid Substances 0.000 description 13
• 230000010076 replication Effects 0.000 description 13
• 239000000758 substrate Substances 0.000 description 13
• 102000018667 ADP-ribosyl Cyclase 1 Human genes 0.000 description 12
• 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 description 12
• 238000004458 analytical method Methods 0.000 description 12
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 12
• 230000002163 immunogen Effects 0.000 description 12
• 201000000050 myeloid neoplasm Diseases 0.000 description 12
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
• 239000000523 sample Substances 0.000 description 12
• 230000001580 bacterial effect Effects 0.000 description 11
• 230000000295 complement effect Effects 0.000 description 11
• 238000000684 flow cytometry Methods 0.000 description 11
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 11
• 230000003053 immunization Effects 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 238000002823 phage display Methods 0.000 description 11
• 239000000047 product Substances 0.000 description 11
• 230000001105 regulatory effect Effects 0.000 description 11
• 230000008685 targeting Effects 0.000 description 11
• 230000003612 virological effect Effects 0.000 description 11
• 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 10
• 241000196324 Embryophyta Species 0.000 description 10
• 241001529936 Murinae Species 0.000 description 10
• 239000002202 Polyethylene glycol Substances 0.000 description 10
• 238000003556 assay Methods 0.000 description 10
• 230000000903 blocking effect Effects 0.000 description 10
• 230000021615 conjugation Effects 0.000 description 10
• 239000002254 cytotoxic agent Substances 0.000 description 10
• 238000013507 mapping Methods 0.000 description 10
• 210000001616 monocyte Anatomy 0.000 description 10
• 229920001223 polyethylene glycol Polymers 0.000 description 10
• 230000035755 proliferation Effects 0.000 description 10
• 230000000717 retained effect Effects 0.000 description 10
• 210000001519 tissue Anatomy 0.000 description 10
• 210000004881 tumor cell Anatomy 0.000 description 10
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
• BQOHYSXSASDCEA-KEOHHSTQSA-N Cyclic ADP-Ribose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=2N=CN3C(C=2N=C1)=N)O)O)OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]3O1 BQOHYSXSASDCEA-KEOHHSTQSA-N 0.000 description 9
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 9
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 9
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 9
• 238000007792 addition Methods 0.000 description 9
• 238000012512 characterization method Methods 0.000 description 9
• 239000002738 chelating agent Substances 0.000 description 9
• 231100000433 cytotoxic Toxicity 0.000 description 9
• 230000000694 effects Effects 0.000 description 9
• 229940099472 immunoglobulin a Drugs 0.000 description 9
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 9
• 238000002703 mutagenesis Methods 0.000 description 9
• 231100000350 mutagenesis Toxicity 0.000 description 9
• 230000035772 mutation Effects 0.000 description 9
• 238000012216 screening Methods 0.000 description 9
• 125000003396 thiol group Chemical group [H]S* 0.000 description 9
• 238000001890 transfection Methods 0.000 description 9
• 238000011830 transgenic mouse model Methods 0.000 description 9
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 8
• 108091034117 Oligonucleotide Proteins 0.000 description 8
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 8
• 108010076504 Protein Sorting Signals Proteins 0.000 description 8
• 230000004075 alteration Effects 0.000 description 8
• 125000000837 carbohydrate group Chemical group 0.000 description 8
• 239000002619 cytotoxin Substances 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 238000013461 design Methods 0.000 description 8
• 238000005516 engineering process Methods 0.000 description 8
• 238000002649 immunization Methods 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 210000004962 mammalian cell Anatomy 0.000 description 8
• 239000003550 marker Substances 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 238000003127 radioimmunoassay Methods 0.000 description 8
• 238000003259 recombinant expression Methods 0.000 description 8
• 229960004641 rituximab Drugs 0.000 description 8
• 230000028327 secretion Effects 0.000 description 8
• 125000001424 substituent group Chemical group 0.000 description 8
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
• 108010053187 Diphtheria Toxin Proteins 0.000 description 7
• 102000016607 Diphtheria Toxin Human genes 0.000 description 7
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 7
• 108010074328 Interferon-gamma Proteins 0.000 description 7
• 238000012449 Kunming mouse Methods 0.000 description 7
• 238000012408 PCR amplification Methods 0.000 description 7
• 241000283984 Rodentia Species 0.000 description 7
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
• 238000013459 approach Methods 0.000 description 7
• 230000004071 biological effect Effects 0.000 description 7
• 150000001875 compounds Chemical class 0.000 description 7
• 230000002255 enzymatic effect Effects 0.000 description 7
• 238000003384 imaging method Methods 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 210000002540 macrophage Anatomy 0.000 description 7
• 238000003752 polymerase chain reaction Methods 0.000 description 7
• 230000006798 recombination Effects 0.000 description 7
• 238000005215 recombination Methods 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 230000005945 translocation Effects 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• 108091023037 Aptamer Proteins 0.000 description 6
• 241000282472 Canis lupus familiaris Species 0.000 description 6
• 101710112752 Cytotoxin Proteins 0.000 description 6
• 238000002965 ELISA Methods 0.000 description 6
• 241000588724 Escherichia coli Species 0.000 description 6
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 108090001005 Interleukin-6 Proteins 0.000 description 6
• 102000004889 Interleukin-6 Human genes 0.000 description 6
• 108060001084 Luciferase Proteins 0.000 description 6
• 239000005089 Luciferase Substances 0.000 description 6
• 241001494479 Pecora Species 0.000 description 6
• 108020004511 Recombinant DNA Proteins 0.000 description 6
• 239000004473 Threonine Substances 0.000 description 6
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
• 230000009824 affinity maturation Effects 0.000 description 6
• 239000002246 antineoplastic agent Substances 0.000 description 6
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 6
• 210000004899 c-terminal region Anatomy 0.000 description 6
• 238000003776 cleavage reaction Methods 0.000 description 6
• 238000010276 construction Methods 0.000 description 6
• 239000003431 cross linking reagent Substances 0.000 description 6
• 230000009260 cross reactivity Effects 0.000 description 6
• 238000001514 detection method Methods 0.000 description 6
• 230000029087 digestion Effects 0.000 description 6
• 239000000539 dimer Substances 0.000 description 6
• 238000010494 dissociation reaction Methods 0.000 description 6
• 230000005593 dissociations Effects 0.000 description 6
• 210000000981 epithelium Anatomy 0.000 description 6
• 210000003527 eukaryotic cell Anatomy 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 229940100601 interleukin-6 Drugs 0.000 description 6
• 210000000822 natural killer cell Anatomy 0.000 description 6
• 210000002381 plasma Anatomy 0.000 description 6
• 230000007017 scission Effects 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 5
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 5
• 241000283690 Bos taurus Species 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 5
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 5
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 5
• 102000004127 Cytokines Human genes 0.000 description 5
• 108090000695 Cytokines Proteins 0.000 description 5
• 238000012450 HuMAb Mouse Methods 0.000 description 5
• 102100037850 Interferon gamma Human genes 0.000 description 5
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 5
• 241000699660 Mus musculus Species 0.000 description 5
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
• 230000009830 antibody antigen interaction Effects 0.000 description 5
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 5
• 229940098773 bovine serum albumin Drugs 0.000 description 5
• 229960004316 cisplatin Drugs 0.000 description 5
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
• 239000002299 complementary DNA Substances 0.000 description 5
• 230000001268 conjugating effect Effects 0.000 description 5
• 235000018417 cysteine Nutrition 0.000 description 5
• 229960002433 cysteine Drugs 0.000 description 5
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
• 230000007423 decrease Effects 0.000 description 5
• 210000003038 endothelium Anatomy 0.000 description 5
• 239000003623 enhancer Substances 0.000 description 5
• 201000003444 follicular lymphoma Diseases 0.000 description 5
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
• 229940072221 immunoglobulins Drugs 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• 210000004185 liver Anatomy 0.000 description 5
• 230000003211 malignant effect Effects 0.000 description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
• 238000011275 oncology therapy Methods 0.000 description 5
• WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 5
• 230000036961 partial effect Effects 0.000 description 5
• 208000031223 plasma cell leukemia Diseases 0.000 description 5
• 102000040430 polynucleotide Human genes 0.000 description 5
• 108091033319 polynucleotide Proteins 0.000 description 5
• 239000002157 polynucleotide Substances 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 230000001177 retroviral effect Effects 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 238000002741 site-directed mutagenesis Methods 0.000 description 5
• 125000006850 spacer group Chemical group 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 230000014616 translation Effects 0.000 description 5
• 241000701161 unidentified adenovirus Species 0.000 description 5
• XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 5
• 206010069754 Acquired gene mutation Diseases 0.000 description 4
• 229940124292 CD20 monoclonal antibody Drugs 0.000 description 4
• 241000701022 Cytomegalovirus Species 0.000 description 4
• 241000287828 Gallus gallus Species 0.000 description 4
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
• 241000175212 Herpesvirales Species 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 4
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
• 241000270322 Lepidosauria Species 0.000 description 4
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 4
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 4
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• 108010039491 Ricin Proteins 0.000 description 4
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
• 108090000631 Trypsin Proteins 0.000 description 4
• 102000004142 Trypsin Human genes 0.000 description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
• 102100040247 Tumor necrosis factor Human genes 0.000 description 4
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
• QOTXBMGJKFVZRD-HISDBWNOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,5r)-5-(3-carboxypyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [N+]1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@@H]([C@@H]2O)OP(O)(O)=O)N2C=3N=CN=C(C=3N=C2)N)=CC=CC(C(O)=O)=C1 QOTXBMGJKFVZRD-HISDBWNOSA-N 0.000 description 4
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
• 230000000692 anti-sense effect Effects 0.000 description 4
• 229960001467 bortezomib Drugs 0.000 description 4
• 229930195731 calicheamicin Natural products 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 235000013330 chicken meat Nutrition 0.000 description 4
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
• 238000010367 cloning Methods 0.000 description 4
• 238000004132 cross linking Methods 0.000 description 4
• 230000002950 deficient Effects 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 210000004524 haematopoietic cell Anatomy 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 244000005700 microbiome Species 0.000 description 4
• 235000013336 milk Nutrition 0.000 description 4
• 239000008267 milk Substances 0.000 description 4
• 210000004080 milk Anatomy 0.000 description 4
• 229940046231 pamidronate Drugs 0.000 description 4
• 210000000496 pancreas Anatomy 0.000 description 4
• 230000002023 papillomaviral effect Effects 0.000 description 4
• 239000002953 phosphate buffered saline Substances 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 239000013615 primer Substances 0.000 description 4
• 210000002307 prostate Anatomy 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 230000037439 somatic mutation Effects 0.000 description 4
• 230000009870 specific binding Effects 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 229960003433 thalidomide Drugs 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 239000012588 trypsin Substances 0.000 description 4
• 210000005253 yeast cell Anatomy 0.000 description 4
• 229960004276 zoledronic acid Drugs 0.000 description 4
• LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 3
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
• HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 3
• FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 3
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
• 102100029824 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Human genes 0.000 description 3
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
• OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 3
• 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 3
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
• 108020004705 Codon Proteins 0.000 description 3
• 206010009944 Colon cancer Diseases 0.000 description 3
• 241000557626 Corvus corax Species 0.000 description 3
• 239000004971 Cross linker Substances 0.000 description 3
• 102000053602 DNA Human genes 0.000 description 3
• 108010092160 Dactinomycin Proteins 0.000 description 3
• DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 3
• 108010029961 Filgrastim Proteins 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
• 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 3
• MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 3
• 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 3
• 102000003812 Interleukin-15 Human genes 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
• BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 101710160107 Outer membrane protein A Proteins 0.000 description 3
• 102000057297 Pepsin A Human genes 0.000 description 3
• 108090000284 Pepsin A Proteins 0.000 description 3
• 239000004365 Protease Substances 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 229920002684 Sepharose Polymers 0.000 description 3
• 108020004459 Small interfering RNA Proteins 0.000 description 3
• 108010022394 Threonine synthase Proteins 0.000 description 3
• DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 3
• 108020004566 Transfer RNA Proteins 0.000 description 3
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
• VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 229940062527 alendronate Drugs 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 230000001093 anti-cancer Effects 0.000 description 3
• 239000002260 anti-inflammatory agent Substances 0.000 description 3
• 229940121363 anti-inflammatory agent Drugs 0.000 description 3
• GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 3
• 229960002594 arsenic trioxide Drugs 0.000 description 3
• 229960000397 bevacizumab Drugs 0.000 description 3
• 230000001588 bifunctional effect Effects 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 210000001772 blood platelet Anatomy 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 210000002798 bone marrow cell Anatomy 0.000 description 3
• 230000001275 ca(2+)-mobilization Effects 0.000 description 3
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
• 239000013592 cell lysate Substances 0.000 description 3
• 229960005395 cetuximab Drugs 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
• 229960002286 clodronic acid Drugs 0.000 description 3
• ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 3
• 230000006957 competitive inhibition Effects 0.000 description 3
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 102000004419 dihydrofolate reductase Human genes 0.000 description 3
• 229960004679 doxorubicin Drugs 0.000 description 3
• 210000002919 epithelial cell Anatomy 0.000 description 3
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
• 229960001433 erlotinib Drugs 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 229940009626 etidronate Drugs 0.000 description 3
• 229960004177 filgrastim Drugs 0.000 description 3
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
• 229960002584 gefitinib Drugs 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 229940015872 ibandronate Drugs 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 210000002865 immune cell Anatomy 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 230000001506 immunosuppresive effect Effects 0.000 description 3
• 239000002596 immunotoxin Substances 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 230000002452 interceptive effect Effects 0.000 description 3
• 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 3
• 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 3
• 238000005304 joining Methods 0.000 description 3
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 3
• 229960004942 lenalidomide Drugs 0.000 description 3
• 210000001165 lymph node Anatomy 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 229960004857 mitomycin Drugs 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 3
• 108010044644 pegfilgrastim Proteins 0.000 description 3
• 229960001373 pegfilgrastim Drugs 0.000 description 3
• 229940111202 pepsin Drugs 0.000 description 3
• 238000010647 peptide synthesis reaction Methods 0.000 description 3
• 210000004180 plasmocyte Anatomy 0.000 description 3
• 230000008488 polyadenylation Effects 0.000 description 3
• 238000001556 precipitation Methods 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 210000001236 prokaryotic cell Anatomy 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 230000000284 resting effect Effects 0.000 description 3
• 108010038379 sargramostim Proteins 0.000 description 3
• 229960002530 sargramostim Drugs 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 230000003393 splenic effect Effects 0.000 description 3
• 210000004988 splenocyte Anatomy 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• ZMELOYOKMZBMRB-DLBZAZTESA-N talmapimod Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)C=2C(=CC=3N(C)C=C(C=3C=2)C(=O)C(=O)N(C)C)Cl)N1CC1=CC=C(F)C=C1 ZMELOYOKMZBMRB-DLBZAZTESA-N 0.000 description 3
• 229940019375 tiludronate Drugs 0.000 description 3
• 230000014621 translational initiation Effects 0.000 description 3
• 230000004614 tumor growth Effects 0.000 description 3
• 229960004528 vincristine Drugs 0.000 description 3
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
• OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• AASYSXRGODIQGY-UHFFFAOYSA-N 1-[1-(2,5-dioxopyrrol-1-yl)hexyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(CCCCC)N1C(=O)C=CC1=O AASYSXRGODIQGY-UHFFFAOYSA-N 0.000 description 2
• OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
• RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
• KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
• VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
• VXPSQDAMFATNNG-UHFFFAOYSA-N 3-[2-(2,5-dioxopyrrol-3-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C(=CC=CC=2)C=2C(NC(=O)C=2)=O)=C1 VXPSQDAMFATNNG-UHFFFAOYSA-N 0.000 description 2
• PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
• GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 2
• 239000013607 AAV vector Substances 0.000 description 2
• 108010046643 ADP-ribosyl cyclase 2 Proteins 0.000 description 2
• 108050008264 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
• 108010066676 Abrin Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 241000710929 Alphavirus Species 0.000 description 2
• 108091093088 Amplicon Proteins 0.000 description 2
• 108010032595 Antibody Binding Sites Proteins 0.000 description 2
• 108010083359 Antigen Receptors Proteins 0.000 description 2
• 102000006306 Antigen Receptors Human genes 0.000 description 2
• 108010024976 Asparaginase Proteins 0.000 description 2
• 102000015790 Asparaginase Human genes 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 229940124295 CD38 monoclonal antibody Drugs 0.000 description 2
• 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 2
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 102100025680 Complement decay-accelerating factor Human genes 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
• 241000702421 Dependoparvovirus Species 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• 102000001301 EGF receptor Human genes 0.000 description 2
• 108060006698 EGF receptor Proteins 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 239000004366 Glucose oxidase Substances 0.000 description 2
• 108010015776 Glucose oxidase Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 2
• 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 2
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
• 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 2
• 101001116302 Homo sapiens Platelet endothelial cell adhesion molecule Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• 108010042653 IgA receptor Proteins 0.000 description 2
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
• 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 102000004195 Isomerases Human genes 0.000 description 2
• 108090000769 Isomerases Proteins 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-Glutamic acid Natural products OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 2
• 229930192392 Mitomycin Natural products 0.000 description 2
• 230000004988 N-glycosylation Effects 0.000 description 2
• KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
• 108091061960 Naked DNA Proteins 0.000 description 2
• 206010028811 Natural killer-cell leukaemia Diseases 0.000 description 2
• 101710163270 Nuclease Proteins 0.000 description 2
• 108091005461 Nucleic proteins Proteins 0.000 description 2
• 230000004989 O-glycosylation Effects 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 206010057249 Phagocytosis Diseases 0.000 description 2
• 208000007452 Plasmacytoma Diseases 0.000 description 2
• 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 2
• 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 2
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
• 102100038358 Prostate-specific antigen Human genes 0.000 description 2
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 2
• 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 238000011579 SCID mouse model Methods 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• 108010067390 Viral Proteins Proteins 0.000 description 2
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 2
• 238000002441 X-ray diffraction Methods 0.000 description 2
• PWJFNRJRHXWEPT-AOOZFPJJSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r)-2,3,4-trihydroxy-5-oxopentyl] hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O)[C@@H](O)[C@H]1O PWJFNRJRHXWEPT-AOOZFPJJSA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000010933 acylation Effects 0.000 description 2
• 238000005917 acylation reaction Methods 0.000 description 2
• 238000012867 alanine scanning Methods 0.000 description 2
• 230000029936 alkylation Effects 0.000 description 2
• 238000005804 alkylation reaction Methods 0.000 description 2
• QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
• 238000010640 amide synthesis reaction Methods 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 210000000628 antibody-producing cell Anatomy 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• 229960003272 asparaginase Drugs 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 2
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 229940000635 beta-alanine Drugs 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 238000006664 bond formation reaction Methods 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 238000012412 chemical coupling Methods 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 229940044683 chemotherapy drug Drugs 0.000 description 2
• VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 239000007822 coupling agent Substances 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 229960000640 dactinomycin Drugs 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
• 229910052805 deuterium Inorganic materials 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 2
• 150000004662 dithiols Chemical class 0.000 description 2
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 235000013601 eggs Nutrition 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 210000004700 fetal blood Anatomy 0.000 description 2
• 229940126864 fibroblast growth factor Drugs 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 238000001476 gene delivery Methods 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 210000001280 germinal center Anatomy 0.000 description 2
• 229940116332 glucose oxidase Drugs 0.000 description 2
• 235000019420 glucose oxidase Nutrition 0.000 description 2
• 102000005396 glutamine synthetase Human genes 0.000 description 2
• 108020002326 glutamine synthetase Proteins 0.000 description 2
• 210000003714 granulocyte Anatomy 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 208000014951 hematologic disease Diseases 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 230000003308 immunostimulating effect Effects 0.000 description 2
• 229960003444 immunosuppressant agent Drugs 0.000 description 2
• 230000001861 immunosuppressant effect Effects 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 230000002637 immunotoxin Effects 0.000 description 2
• 229940051026 immunotoxin Drugs 0.000 description 2
• 231100000608 immunotoxin Toxicity 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000008676 import Effects 0.000 description 2
• APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 2
• 229940055742 indium-111 Drugs 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 108010044426 integrins Proteins 0.000 description 2
• 102000006495 integrins Human genes 0.000 description 2
• 229960003130 interferon gamma Drugs 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 150000002540 isothiocyanates Chemical class 0.000 description 2
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 210000003563 lymphoid tissue Anatomy 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
• 229960001924 melphalan Drugs 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
• 229960001156 mitoxantrone Drugs 0.000 description 2
• 108010010621 modeccin Proteins 0.000 description 2
• 230000009149 molecular binding Effects 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 238000003032 molecular docking Methods 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 210000004400 mucous membrane Anatomy 0.000 description 2
• 208000025113 myeloid leukemia Diseases 0.000 description 2
• 210000000107 myocyte Anatomy 0.000 description 2
• 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 229960003966 nicotinamide Drugs 0.000 description 2
• 235000005152 nicotinamide Nutrition 0.000 description 2
• 239000011570 nicotinamide Substances 0.000 description 2
• 210000003463 organelle Anatomy 0.000 description 2
• 210000002997 osteoclast Anatomy 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 230000008782 phagocytosis Effects 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• 239000013600 plasmid vector Substances 0.000 description 2
• 229960003171 plicamycin Drugs 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 208000022256 primary systemic amyloidosis Diseases 0.000 description 2
• 238000007639 printing Methods 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• 238000001243 protein synthesis Methods 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 230000005180 public health Effects 0.000 description 2
• 210000000449 purkinje cell Anatomy 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 238000010791 quenching Methods 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 210000003660 reticulum Anatomy 0.000 description 2
• 230000002207 retinal effect Effects 0.000 description 2
• 210000003705 ribosome Anatomy 0.000 description 2
• 210000000518 sarcolemma Anatomy 0.000 description 2
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 230000007781 signaling event Effects 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 210000002460 smooth muscle Anatomy 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 210000001082 somatic cell Anatomy 0.000 description 2
• 230000000392 somatic effect Effects 0.000 description 2
• 210000003699 striated muscle Anatomy 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 229960005486 vaccine Drugs 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• 229960000237 vorinostat Drugs 0.000 description 2
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
• BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
• BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
• KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
• JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
• VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
• FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
• 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
• 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
• 108020005345 3' Untranslated Regions Proteins 0.000 description 1
• XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
• 229940117976 5-hydroxylysine Drugs 0.000 description 1
• SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
• 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
• 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 241000701242 Adenoviridae Species 0.000 description 1
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
• 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
• 108010025188 Alcohol oxidase Proteins 0.000 description 1
• 102100022987 Angiogenin Human genes 0.000 description 1
• 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
• 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
• 208000004736 B-Cell Leukemia Diseases 0.000 description 1
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 101150002659 CD38 gene Proteins 0.000 description 1
• 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
• 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 102100035882 Catalase Human genes 0.000 description 1
• 108010053835 Catalase Proteins 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000256135 Chironomus thummi Species 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 102100023804 Coagulation factor VII Human genes 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
• 229930182847 D-glutamic acid Natural products 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 101100012887 Drosophila melanogaster btl gene Proteins 0.000 description 1
• 101100012878 Drosophila melanogaster htl gene Proteins 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 102100038591 Endothelial cell-selective adhesion molecule Human genes 0.000 description 1
• 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
• 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 1
• 108010023321 Factor VII Proteins 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
• 108700023863 Gene Components Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 206010056740 Genital discharge Diseases 0.000 description 1
• 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
• 102100022624 Glucoamylase Human genes 0.000 description 1
• 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
• 108010091938 HLA-B7 Antigen Proteins 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
• 101710182312 High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
• 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
• 101000882622 Homo sapiens Endothelial cell-selective adhesion molecule Proteins 0.000 description 1
• 101001036689 Homo sapiens Melanoma-associated antigen B5 Proteins 0.000 description 1
• 101001036675 Homo sapiens Melanoma-associated antigen B6 Proteins 0.000 description 1
• 101001057159 Homo sapiens Melanoma-associated antigen C3 Proteins 0.000 description 1
• 101000821981 Homo sapiens Sarcoma antigen 1 Proteins 0.000 description 1
• 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 101000648075 Homo sapiens Trafficking protein particle complex subunit 1 Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 241000725303 Human immunodeficiency virus Species 0.000 description 1
• LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• 108010073807 IgG Receptors Proteins 0.000 description 1
• 102000009490 IgG Receptors Human genes 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 101150008942 J gene Proteins 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 206010023791 Large granular lymphocytosis Diseases 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 108010010995 MART-1 Antigen Proteins 0.000 description 1
• 102000016200 MART-1 Antigen Human genes 0.000 description 1
• 101100438926 Macaca fascicularis CD38 gene Proteins 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
• 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
• 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
• 102100039475 Melanoma-associated antigen B5 Human genes 0.000 description 1
• 102100039483 Melanoma-associated antigen B6 Human genes 0.000 description 1
• 102100027248 Melanoma-associated antigen C3 Human genes 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 244000302512 Momordica charantia Species 0.000 description 1
• 235000009811 Momordica charantia Nutrition 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 108010008707 Mucin-1 Proteins 0.000 description 1
• 102000007298 Mucin-1 Human genes 0.000 description 1
• 108010063954 Mucins Proteins 0.000 description 1
• 102000015728 Mucins Human genes 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• OLNLSTNFRUFTLM-UHFFFAOYSA-N N-ethylasparagine Chemical compound CCNC(C(O)=O)CC(N)=O OLNLSTNFRUFTLM-UHFFFAOYSA-N 0.000 description 1
• YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
• 108010065338 N-ethylglycine Proteins 0.000 description 1
• AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
• 241001045988 Neogene Species 0.000 description 1
• 102000048850 Neoplasm Genes Human genes 0.000 description 1
• 108700019961 Neoplasm Genes Proteins 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
• 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 206010034623 Peripheral T-cell lymphoma unspecified Diseases 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 244000046052 Phaseolus vulgaris Species 0.000 description 1
• 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
• 108010064785 Phospholipases Proteins 0.000 description 1
• 102000015439 Phospholipases Human genes 0.000 description 1
• 108010053210 Phycocyanin Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 240000007643 Phytolacca americana Species 0.000 description 1
• 235000009074 Phytolacca americana Nutrition 0.000 description 1
• 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
• 231100000742 Plant toxin Toxicity 0.000 description 1
• 208000024588 Primary cutaneous follicle center lymphoma Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
• 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 102100029796 Protein S100-A10 Human genes 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 108091034057 RNA (poly(A)) Proteins 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 108090000621 Ribonuclease P Proteins 0.000 description 1
• 102000004167 Ribonuclease P Human genes 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 108010084592 Saporins Proteins 0.000 description 1
• 102100021466 Sarcoma antigen 1 Human genes 0.000 description 1
• 108010077895 Sarcosine Proteins 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 208000009359 Sezary Syndrome Diseases 0.000 description 1
• 108010079723 Shiga Toxin Proteins 0.000 description 1
• 108010091769 Shiga Toxin 1 Proteins 0.000 description 1
• 108010090763 Shiga Toxin 2 Proteins 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 241000251131 Sphyrna Species 0.000 description 1
• 241000269319 Squalius cephalus Species 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
• 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 108010055044 Tetanus Toxin Proteins 0.000 description 1
• 241000223892 Tetrahymena Species 0.000 description 1
• HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 102100025256 Trafficking protein particle complex subunit 1 Human genes 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
• 102000014384 Type C Phospholipases Human genes 0.000 description 1
• 108010079194 Type C Phospholipases Proteins 0.000 description 1
• 102100039094 Tyrosinase Human genes 0.000 description 1
• 108060008724 Tyrosinase Proteins 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 108010046334 Urease Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 240000001866 Vernicia fordii Species 0.000 description 1
• IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
• PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 108700010877 adenoviridae proteins Proteins 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 201000006966 adult T-cell leukemia Diseases 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 108010004469 allophycocyanin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• 108010001818 alpha-sarcin Proteins 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 150000001408 amides Chemical group 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229960002684 aminocaproic acid Drugs 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 239000002870 angiogenesis inducing agent Substances 0.000 description 1
• 108010072788 angiogenin Proteins 0.000 description 1
• 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 238000011091 antibody purification Methods 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• RYXHOMYVWAEKHL-OUBTZVSYSA-N astatine-211 Chemical compound [211At] RYXHOMYVWAEKHL-OUBTZVSYSA-N 0.000 description 1
• 230000003416 augmentation Effects 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000008033 biological extinction Effects 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 150000001639 boron compounds Chemical class 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229960005069 calcium Drugs 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229960001714 calcium phosphate Drugs 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 229940022399 cancer vaccine Drugs 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000005859 cell recognition Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 210000003763 chloroplast Anatomy 0.000 description 1
• 238000011098 chromatofocusing Methods 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• BJBUEDPLEOHJGE-IUYQGCFVSA-N cis-3-hydroxy-D-proline zwitterion Chemical compound O[C@H]1CCN[C@H]1C(O)=O BJBUEDPLEOHJGE-IUYQGCFVSA-N 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 239000008139 complexing agent Substances 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 238000005695 dehalogenation reaction Methods 0.000 description 1
• RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
• VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229930191339 dianthin Natural products 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 238000002050 diffraction method Methods 0.000 description 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 229960005501 duocarmycin Drugs 0.000 description 1
• 229930184221 duocarmycin Natural products 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 108010028531 enomycin Proteins 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 229940012413 factor vii Drugs 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 230000033581 fucosylation Effects 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 150000002270 gangliosides Chemical class 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 238000012637 gene transfection Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 150000002337 glycosamines Chemical group 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 229940096329 human immunoglobulin a Drugs 0.000 description 1
• 229940098197 human immunoglobulin g Drugs 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
• 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 150000002463 imidates Chemical class 0.000 description 1
• 239000012642 immune effector Substances 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 230000003426 interchromosomal effect Effects 0.000 description 1
• 230000017306 interleukin-6 production Effects 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 229940044173 iodine-125 Drugs 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
• 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 229910052747 lanthanoid Inorganic materials 0.000 description 1
• 150000002602 lanthanoids Chemical class 0.000 description 1
• 150000002605 large molecules Chemical class 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
• 235000020778 linoleic acid Nutrition 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 208000007282 lymphomatoid papulosis Diseases 0.000 description 1
• 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 238000009115 maintenance therapy Methods 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
• 208000021937 marginal zone lymphoma Diseases 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 201000000638 mature B-cell neoplasm Diseases 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960003151 mercaptamine Drugs 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
• 238000012737 microarray-based gene expression Methods 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 238000000302 molecular modelling Methods 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• QOSWSNDWUATJBJ-UHFFFAOYSA-N n,n'-diphenyloctanediamide Chemical compound C=1C=CC=CC=1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 QOSWSNDWUATJBJ-UHFFFAOYSA-N 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 230000007302 negative regulation of cytokine production Effects 0.000 description 1
• 230000017066 negative regulation of growth Effects 0.000 description 1
• 101150091879 neo gene Proteins 0.000 description 1
• 208000010915 neoplasm of mature B-cells Diseases 0.000 description 1
• 208000021119 neoplasm of mature T-cells or NK-cells Diseases 0.000 description 1
• 230000003448 neutrophilic effect Effects 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 230000030648 nucleus localization Effects 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 238000004091 panning Methods 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 210000003681 parotid gland Anatomy 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 230000001175 peptic effect Effects 0.000 description 1
• 230000016446 peptide cross-linking Effects 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
• 108010076042 phenomycin Proteins 0.000 description 1
• RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
• 125000000405 phenylalanyl group Chemical group 0.000 description 1
• 125000005642 phosphothioate group Chemical group 0.000 description 1
• 239000000906 photoactive agent Substances 0.000 description 1
• ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 239000003123 plant toxin Substances 0.000 description 1
• 150000003057 platinum Chemical class 0.000 description 1
• 108700028325 pokeweed antiviral Proteins 0.000 description 1
• 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 230000005892 protein maturation Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 239000002287 radioligand Substances 0.000 description 1
• 239000012217 radiopharmaceutical Substances 0.000 description 1
• 229940121896 radiopharmaceutical Drugs 0.000 description 1
• 230000002799 radiopharmaceutical effect Effects 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 229910052702 rhenium Inorganic materials 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 235000002020 sage Nutrition 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000000243 solution Substances 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
• 238000011476 stem cell transplantation Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000004354 sulfur functional group Chemical group 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
• 229940056501 technetium 99m Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 229940118376 tetanus toxin Drugs 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• 229940034915 thalomid Drugs 0.000 description 1
• IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 1
• YSMODUONRAFBET-WHFBIAKZSA-N threo-5-hydroxy-L-lysine Chemical compound NC[C@@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-WHFBIAKZSA-N 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
• 229960001479 tosylchloramide sodium Drugs 0.000 description 1
• 238000012549 training Methods 0.000 description 1
• 238000012448 transchromosomic mouse model Methods 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000004565 tumor cell growth Effects 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 229940125575 vaccine candidate Drugs 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229940099039 velcade Drugs 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
• 229940002005 zometa Drugs 0.000 description 1